Growth differentiation factor 15 impairs aortic contractile and relaxing function through altered caveolar signaling of the endothelium

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 5, 2013, Pages

  Mazagova, Magdalena ^a,b   Buikema, Hendrik ^a,b   Landheer, Sjoerd W ^a,b   Vavrinec, Peter ^a,b   van Buiten, Azuwerus ^a,b   Henning, Robert H ^a,b   Deelman, Leo E ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Aorta; Caveolae; Caveolin 1; Endothelium; Growth differentiation factor 15; Mice

Indexed keywords

ACETYLCHOLINE; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GROWTH DIFFERENTIATION FACTOR 15; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CAVEOLA; CONTROLLED STUDY; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; AORTA, THORACIC; CAVEOLAE; CAVEOLIN 1; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GROWTH DIFFERENTIATION FACTOR 15; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; REACTIVE OXYGEN SPECIES; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION; VASODILATION;

EID: 84874600793     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00543.2012     Document Type: Article

References (37)

1. Barton CH, Ni Z, Vaziri ND. Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int 60: 1083-1087, 2001.
2. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol Cell Physiol 271: C1424-C1437, 1996.
3. Bernatchez P, Sharma A, Bauer PM, Marin E, Sessa WC. A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOSderived NO synthesis and vasodilation in mice. J Clin Invest 121: 3747-3755, 2011.
4. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci USA 94: 11514-11519, 1997.
5. -/- mice. Am J Physiol Heart Circ Physiol 299: H386-H395, 2010.
6. Carstensen M, Herder C, Brunner EJ, Strassburger K, Tabak AG, Roden M, Witte DR. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol 162: 913-917, 2010.
7. Cheng H, Wang H, Fan X, Paueksakon P, Harris RC. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int 82: 1176-1183, 2012.
8. Das M, Das DK. Caveolae, caveolin, and cavins: potential targets for the treatment of cardiac disease. Ann Med 44: 530-541, 2012.
9. Dostalova I, Roubicek T, Bartlova M, Mraz M, Lacinova Z, Haluzikova D, Kavalkova P, Matoulek M, Kasalicky M, Haluzik M. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol 161: 397-404, 2009.
10. Drexler H, Hornig B. Importance of endothelial function in chronic heart failure. J Cardiovasc Pharmacol 27, Suppl 2: S9-S12, 1996.
11. Giles TD, Sander GE, Nossaman BD, Kadowitz PJ. Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens (Greenwich) 14: 198-205, 2012.
12. Hellemons ME, Mazagova M, Gansevoort RT, Henning RH, De Zeeuw D, Bakker SJ, Lambers-Heerspink HJ, Deelman LE. Growthdifferentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care 35: 2340-2346, 2012.
13. Horvat S, Bunger L. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay for the mouse leptin receptor (Leprdb) mutation. Lab Anim 33: 380-384, 1999.
14. Kamata K, Kojima S. Characteristics of contractile responses of aorta to norepinephrine in db/db mice. Res Commun Mol Pathol Pharmacol 96: 319-328, 1997.
15. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98: 351-360, 2006.
16. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17: 581-588, 2011.
17. Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 30: 1057-1065, 2009.
18. Komori K, Vanhoutte PM. Endothelium-derived hyperpolarizing factor. Blood Vessels 27: 238-245, 1990.
19. Koniaris LG. Induction of MIC-1/growth differentiation factor-15 following bile duct injury. J Gastrointest Surg 7: 901-905, 2003.
20. Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P. Plasma growth differentiation factor-15 (GDF-15) independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 33: 1567-1572, 2010.
21. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, Olofsson S, Venge P, Larsson A, Hulthe J, Elmgren A, Wollert KC. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Eur Heart J 30: 2346-2353, 2009.
22. Mineo C, Shaul PW. Regulation of eNOS in caveolae. Adv Exp Med Biol 729: 51-62, 2012.
23. Moustakas A, Heldin CH. The regulation of TGFβ signal transduction. Development 136: 3699-3714, 2009.
24. Nakamura R, Egashira K, Arimura K, Machida Y, Ide T, Tsutsui H, Shimokawa H, Takeshita A. Increased inactivation of nitric oxide is involved in impaired coronary flow reserve in heart failure. Am J Physiol Heart Circ Physiol 281: H2619-H2625, 2001.
25. Nickel N, Kempf T, Wollert K, Maus U, Olsson K, DeWall C, Welte T, Hoeper M. Growth-Differentiation Factor-15 Is Triggered by Hypoxic Conditions in Endothelial Cells. Vienna: European Respiratory Society Conference, 2009.
26. Samarska IV, van MM, Buikema H, Houwertjes MC, Wulfert FM, Molema G, Epema AH, Henning RH. Adjunct nitrous oxide normalizes vascular reactivity changes after hemorrhagic shock in mice under isoflurane anesthesia. Anesthesiology 111: 600-608, 2009.
27. Sandovici M, Henning RH, van GH, Helfrich W, De ZD, Deelman LE. Systemic gene therapy with interleukin-13 attenuates renal ischemiareperfusion injury. Kidney Int 73: 1364-1373, 2008.
28. van Dokkum RP, Buikema H. Possible new druggable targets for the treatment of nephrosis. Perhaps we should find them in caveolea? Curr Opin Pharmacol 9: 132-138, 2009.
29. Vavrinec P, van Dokkum RP, Goris M, Buikema H, Henning RH. Losartan protects mesenteric arteries from ROS-associated decrease in myogenic constriction following 5/6 nephrectomy. J Renin Angiotensin Aldosterone Syst 12: 184-194, 2011.
30. Wollert KC. Growth-differentiation factor-15 in cardiovascular disease: from bench to bedside, and back. Basic Res Cardiol 102: 412-415, 2007.
31. Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 9: 337-345, 2012.
32. Xu X, Li Z, Gao W. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers 16: 466-475, 2011.
33. Xu Y, Buikema H, Van Gilst WH, Henning RH. Caveolae and endothelial dysfunction: filling the caves in cardiovascular disease. Eur J Pharmacol 585: 256-260, 2008.
34. Xu Y, Henning RH, van der Want JJ, van BA, Van Gilst WH, Buikema H. Disruption of endothelial caveolae is associated with impairment of both NO-as well as EDHF in acetylcholine-induced relaxation depending on their relative contribution in different vascular beds. Life Sci 80: 1678-1685, 2007.
35. Yamamoto E, Nakamura T, Kataoka K, Tokutomi Y, Dong YF, Fukuda M, Nako H, Yasuda O, Ogawa H, Kim-Mitsuyama S. Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. Biochem Biophys Res Commun 403: 258-263, 2010.
36. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 23: 543-548, 2005.
37. Zimmers TA, Jin X, Hsiao EC, Perez EA, Pierce RH, Chavin KD, Koniaris LG. Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor-independent mechanisms. J Surg Res 130: 45-51, 2006.